Verastem (VSTM)

[DrHarleyboy]

“The data presented at SOHO this year highlight the outcomes from the Phase 3 DUO study in the labeled indication, as well as supplemental lymphocytosis data, and continue to support its ongoing use in patients with relapsed or refractory CLL/SLL,” said Hagop Youssoufian, MSc, M.D., Head of Medical Strategy at Verastem Oncology. “These findings not only support the ongoing use of duvelisib in its labeled indication for patients with relapsed or refractory CLL/SLL, but they also suggest that therapy with duvelisib may offer promise warranting further investigation in patients with refractory MZL, for whom limited treatment options exist.”

https://ih.advfn.com/stock-market/NASDAQ/verastem-VSTM/stock-news/80649387/verastem-oncology-announces-copiktra-duvelisib-pr


This is the most promising Biotech in my portfolio right now.